Global biopharmaceutical company Bristol-Myers Squibb Company acquires ZymoGenetics, Inc.
On September 7, global biopharmaceutical company Bristol-Myers Squibb Company and ZymoGenetics, Inc. announced that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb for an aggregate purchase price of approximately $885 million (approximately $735 million net of cash acquired). Willkie advised Warburg Pincus in its role as a significant stockholder in ZymoGenetics in the transaction. ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The deal was handled by partners Steven Gartner and Robert Langdon, and associate Corby Baumann.